Clinical Trials Search
Clinical Trial 20614
Cancer Type: Genitourinary
Study Type: Treatment
NCT#: NCT04338269
Phase: Phase III
Prinicipal Investigator: Jad Chahoud
Study Title
A Phase III, Multicneter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib versus Cabozantinib Alone in Patients with Inoperable, Locally, Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment
Summary
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.
Objective
This study will evaluate the efficacy and safety of atezolizumab when given in combination with cabozantinib (Atezo; Cabo) compared with cabozantinib alone in patients with advanced clear cell or non;clear cell RCC (papillary or unclassified only) who experienced radiographic tumor progression during or after ICI treatment in the metastatic setting.
Therapies
Medications
Atezolizumab (Tecentriq); Cabozantinib (XL 184)
Inclusion Criteria:
Exclusion Criteria:
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.